Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT03912415 2020-09-18

FERMATA

Phase 3 Unknown

316 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00652119 2020-08-19

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Phase 1 Unknown

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03220932 2019-11-01

HIPOVA-01

Phase 3 Unknown

132 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT03912402 2019-05-09

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Phase 2 Unknown

49 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03611179 2018-08-02

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Phase 2 Unknown

40 enrolled

Gynecologic

Advanced Ovarian Cancer

NCT03095001 2017-04-13

Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

Phase 2 Unknown

70 enrolled

Gynecologic

Ovarian Neoplasms

NCT01838538 2013-04-24

Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

Phase 2 Unknown

54 enrolled

Gynecologic

Ovarian Cancer With Malignant Ascites

NCT01770171 2013-01-17

MITOBEVAEND2

Phase 2 Unknown

108 enrolled

Gynecologic

Endometrial Neoplasms

Clinical Trials

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

BEACON

SELENIUM

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

MITO16/MANGO-2

MITO16MANGO2b

Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

BOLD

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

MITO25

NItCHE-MITO33

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

AVANIRA3

FERMATA

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

HIPOVA-01

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

MITOBEVAEND2